COVID-19 is causing a renaissance in the UK biotech sector, we must ensure it lasts
pharmaphorum
AUGUST 27, 2020
Over the past five to ten years US investors have focused on technology and internet companies, and relatively little on new biotech or pharmaceutical companies. In the UK, structural problems of the AIM market have compounded these problems by driving institutional investors away from relatively illiquid shares.
122 
Let's personalize your content